16-Sep-2020 - LANXESS AG

LANXESS plans to expand capacity for Oxone monopersulfate - a main active ingredient for disinfectants

Significant increase in demand due to African swine fever and corona pandemic

Due to the continuous strong demand for disinfectants, specialty chemicals company LANXESS is planning to expand its production capacity for Oxone monopersulfate by around 50 percent. To this end, the company intends to invest a lower double-digit million euro sum in its production facility in Memphis, USA.

LANXESS uses Oxone monopersulfate as the main active ingredient in many of its Virkon and Rely+On disinfection products. Demand for these products has increased significantly in recent months due to, amongst others, the outbreak of African swine fever as well as the corona pandemic. The company also sells Oxone as a powerful oxidizing agent for numerous other applications. The capacity expansion is expected to be completed in the second half of 2022.

“Disinfection products are important growth drivers in our highly profitable Consumer Protection segment. We expect a sustainable high level of demand even after the corona pandemic,” said Matthias Zachert, Chairman of the LANXESS Board of Management.

Michael Schäfer, head of LANXESS' Material Protection Products business unit, added: “We are also seeing a growing demand for Oxone in the water treatment sector as well as from the electronics and paper industries. We want to meet this demand by expanding our production capacity.”

Facts, background information, dossiers
More about Lanxess
  • News

    Biotechnology for soaking and liming

    The X-Zyme process launched by LANXESS is a technology for the beamhouse stage of the leather production process. “The use of two microbial enzymes in the soaking and liming noticeably improves the quality of the pelt, reduces the amount of waste and makes the entire process much more effic ... more

    evocatal draws two new investors as it closes €3.5m Series B round

    evocatal GmbH has completed a Series B financing round. All of the company's existing investors took part, along with new investors NRW.BANK and LANXESS. In realizing the next step of its growth strategy, evocatal has partnered with two new investors: LANXESS and NRW.BANK. The investments f ... more

    Saltigo undertakes major expansion of production

    Saltigo, a wholly owned subsidiary of LANXESS, is significantly expanding production at its Leverkusen site. This is being made possible by a cooperation agreement that is so far unique for the Group. Syngenta is investing some EUR 50 million in expanding several Saltigo facilities in Lever ... more